Business
Stem Cell Therapy
Organoid
Stem Cell and CDMO Business
R&D
Core Technology
Press Release
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Kangstem Biotech Discusses Global Partnership With 'OSCA' At BioEurope
31
2025.10
- Global clinical expansion of osteoarthritis treatment and accelerating organoid platform business
Kangstem Biotech announced that it will participate in “Bio Europe 2025”, which will be held in Vienna, Austria, for four days starting November 3, 2025. Bio Europe is known as one of the most representative events in Europe for strategic business partnerships and networking among biotechnology companies, global pharmaceutical firms, and investors.
This year’s event will feature a business partnering program centered on one-on-one meetings. Through these meetings, Kangstem Biotech plans to actively pursue follow-up discussions with existing partners and explore new technological collaborations, focusing on two key areas:
• OSCA, its knee osteoarthritis treatment
• its skin organoid-based disease modeling platform.
In particular, the company is preparing in-depth meetings with European pharmaceutical companies that possess global supply chains, U.S. biotech firms with osteoarthritis treatment pipelines, and Japanese big pharma companies.
A company representative stated, “This year’s Bio Europe will serve as a pivotal turning point in expanding OSCA’s global clinical development and technology transfer collaborations, as well as accelerating the commercialization timeline for our organoid platform.” They added, “Through these partnership discussions, Kangstem Biotech will take another step closer to realizing its global expansion blueprint.” The spokesperson also noted that “a separate meeting with a U.S. osteoarthritis drug developer is scheduled after the event, reflecting the growing global interest in OSCA since its Phase 1 clinical trial.”
Earlier, on October 23, Kangstem Biotech was invited to present at the 4th Asian Conference of Cartilage and Osteoarthritis (ACCO) corporate session, where it shared updates on the ongoing R&D progress of OSCA. The presentation covered Phase 1 clinical and 12-month follow-up results, including MRI analyses, demonstrating that OSCA provides long-lasting pain relief and improved joint function for over a year, garnering strong interest from experts across Asia.
Kangstem Biotech plans to continue advancing the clinical research, technological sophistication, and commercialization of its main pipelines—the OSCA knee osteoarthritis treatment and the organoid platform—while accelerating license-out (L/O) agreements and global co-development partnerships based on successful clinical outcomes.
For more details, please refer to the link below
[약업신문]강스템바이오텍, 바이오유럽서 오스카-오가노이드 글로벌파트너십 논의
#kangstembiotech #stemcell #cell #stemcelltherapy #celltreatment #osteoarthritis #OSCA
▲ The 4th Asian Conference of Cartilage and Osteoarthritis (ACCO) Industrial Session presented Kangstem Biotech on the theme of 'Advancing Osteoarthritis Treatment with MSC-based Combination Products: A Novel Therapeutics Approach of OSCA'